Related Experiment Video
Updated: Aug 10, 2026

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
Published on: August 28, 2015
Developing Mixed Micelle Delivery Systems for Aromatase Inhibitors
Sheetal Vermani1, Palwinder Singh1, Varinder Kaur1
1Department of Chemistry, Guru Nanak Dev University, Amritsar 143005, India.
Abstract:
Aromatase, an enzyme that facilitates the last stage in estrogen synthesis (estrogen is identified for a significant impact in the development of breast cancer), has been recognized as a potential target for therapeutic advancements for cancer. Although clinically approved aromatase inhibitors are the cornerstones of estrogen receptor-positive (ER+) breast cancer, their use is often accompanied by adverse side effects and pharmacokinetic limitations, which lead to patient compliance issues and limit therapeutic outcomes. In previous studies, compound 1-(a) was identified for its superior inhibition of aromatase with an IC50 value of 54.0 nM and appreciable tumor growth inhibitory activities. Here, we demonstrated the pharmaceutical capability of 1-(a) while evaluating its various features, including acute toxicity, bioavailability by developing a nanodrug delivery system, and therapeutic efficacy. In vivo acute toxicity studies confirmed the safety of compound 1-(a), with no significant alterations observed. To improve the aqueous solubility and pharmacokinetic profile, a mixed micelle-based delivery system by using Pluronics P123 and F127 was developed, and a 2:1 formulation was optimized for demonstrating excellent drug loading (8.8%) and entrapment efficiency (80%). The micellar formulation significantly enhanced the solubility, stability, % growth inhibition, and cellular uptake of 1-(a) against MCF-7 and MDA-MB-231 cell lines and intestine permeability. An in vitro drug release study performed at pH 1.2, 6.8, and 7.4 indicated the sustained release behavior of 1-(a). Overall, the results of these experiments supported the potential of Pluronics as a drug delivery system for the potent aromatase inhibitor.
Insights
A novel nanodrug delivery system using Pluronics enhances the efficacy of compound 1-(a), a potent aromatase inhibitor, for breast cancer therapy. This formulation improves solubility and bioavailability, showing promising therapeutic potential with minimal toxicity.
Area of Science:
- Pharmaceutical Science
- Nanotechnology
- Oncology
Background:
- Aromatase is a key enzyme in estrogen synthesis and a therapeutic target for estrogen receptor-positive (ER+) breast cancer.
- Existing aromatase inhibitors have limitations including adverse side effects and poor pharmacokinetics, impacting treatment outcomes.
- Compound 1-(a) previously showed potent aromatase inhibition (IC50 = 54.0 nM) and tumor growth inhibition.
Purpose of the Study:
- To evaluate the pharmaceutical viability of compound 1-(a) by assessing its toxicity, bioavailability, and therapeutic efficacy.
- To develop and optimize a nanodrug delivery system to improve the solubility and pharmacokinetic profile of compound 1-(a).
- To investigate the in vitro and in vivo performance of the developed nanodrug formulation.
Main Methods:
- In vivo acute toxicity studies were conducted to assess the safety of compound 1-(a).
- A mixed micelle-based delivery system using Pluronics P123 and F127 was developed and optimized (2:1 formulation).
- The nanomicellar formulation's drug loading (8.8%), entrapment efficiency (80%), solubility, stability, cellular uptake (MCF-7, MDA-MB-231), and in vitro drug release were evaluated.
Main Results:
- Compound 1-(a) demonstrated safety in acute toxicity studies with no significant adverse effects.
- The optimized Pluronics-based micellar formulation significantly improved compound 1-(a)'s solubility, stability, and cellular uptake.
- The formulation exhibited sustained drug release characteristics across different pH conditions (1.2, 6.8, 7.4).
Conclusions:
- Pluronics P123 and F127 form an effective mixed micelle delivery system for the potent aromatase inhibitor compound 1-(a).
- The developed nanodrug formulation enhances the pharmaceutical properties and therapeutic potential of compound 1-(a) for breast cancer treatment.
- This study supports the use of Pluronics as a viable drug delivery strategy for potent aromatase inhibitors.
Related Concept Videos
Bioavailability Enhancement: Drug Permeability Enhancement
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Modified-Release Drug Delivery Systems: Site-Targeted
Micelles
Intrauterine Drug Delivery Systems
Modified-Release Drug Delivery Systems: Rate-Programmed II

